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in Zebrafish Identify GTDC2 Mutations
as a Cause of Walker-Warburg Syndrome
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Whole-exome sequencing (WES), which analyzes the coding sequence of most annotated genes in the human genome, is an ideal
approach to studying fully penetrant autosomal-recessive diseases, and it has been very powerful in identifying disease-causing muta-
tions even when enrollment of affected individuals is limited by reduced survival. In this study, we combined WES with homozygosity
analysis of consanguineous pedigrees, which are informative even when a single affected individual is available, to identify genetic
mutations responsible for Walker-Warburg syndrome (WWS), a genetically heterogeneous autosomal-recessive disorder that severely
affects the development of the brain, eyes, and muscle. Mutations in seven genes are known to cause WWS and explain 50%–60% of
cases, but multiple additional genes are expected to be mutated because unexplained cases show suggestive linkage to diverse loci. Using
WES in consanguineous WWS-affected families, we found multiple deleterious mutations in GTDC2 (also known as AGO61). GTDC2’s
predicted role as an uncharacterized glycosyltransferase is consistent with the function of other genes that are known to be mutated in
WWS and that are involved in the glycosylation of the transmembrane receptor dystroglycan. Therefore, to explore the role of GTDC2
loss of function during development, we used morpholino-mediated knockdown of its zebrafish ortholog, gtdc2. We found that gtdc2
knockdown in zebrafish replicates all WWS features (hydrocephalus, ocular defects, and muscular dystrophy), strongly suggesting
that GTDC2 mutations cause WWS.Walker-Warburg syndrome (WWS, also known as
MDDGA1–7 [MIM 236670, 613150, 253280, 253800,
613153, 613154, and 614643]) is a severe neuromuscular
disorder characterized by congenital muscular dystrophy,
ocular malformations, smooth appearance of the cortical
surface accompanied by neuronal migration defects
(cobblestone lissencephaly), and ventricular enlargement
(hydrocephalus).1,2 Mutations in seven genes (POMT1
[MIM 607423], POMT2 [MIM 607439], POMGNT1 [MIM
606822], FKTN [MIM 607440], FKRP [MIM 606596],
LARGE [MIM 603590], and ISPD [MIM 614631]) are known
to cause WWS2–5 but are only identified in 50%–60% of
cases.4,6–8 Identification of additional genes mutated in
WWS has been hindered by the small size of the available
pedigrees, from which DNA is only available from one or
two affected individuals. To increase our power to under-
stand the genetic architecture of WWS and to identify
mutations in additional genes, we collected a cohort of
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All affected individuals were diagnosed with classic WWS
on the basis of the following criteria: (1) brain malfor-
mation characterized by cobblestone lissencephaly on
neuroimaging, severe hydrocephalus, and cerebellar
hypoplasia; (2) the presence of ocular malformations
(microphthalmia and macrophthalmia, retinal dysplasia,
optic nerve hypoplasia, and anterior chamber defects);
and (3) a clinical diagnosis, usually based on severe hypo-
tonia, of congenital muscular dystrophy.1,9 Serum creatine
kinase and histopathological confirmation of muscular
dystrophy were not available in most cases because of
the clinical severity and reduced lifespan associated with
this condition.
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Table 1. Clinical Features of Individuals with FKTN, POMT2, or GTDC2 Mutations
Person Age at Exam Gene
Cobblestone
Lissencephaly
Enlarged
Ventricles
Cerebellar
Hypoplasia Ocular Defects Muscular Defects
82-1 2 months FKTN þ þ þ retinal dysplasia,
glaucoma
CK ¼ 44,566 U/la
144-1 6 months POMT2 þ þ þ glaucoma hypotonia
86-1 23 weeks GTDC2 þ þ þ  
86-2 20 weeks þ þ þ N/A N/A
90-1 2 months GTDC2 þ þ þ retinal dysplasia hypotonia
100-1 1 month GTDC2 þ þ þ microphthalmia and
macrophthalmia
hypotonia
The following abbreviations are used: CK, creatine kinase; and N/A, not available.
aNormal CK range: 40–180 U/l.DNA from the probands and all available family members
on whole-genome SNP arrays—Affymetrix 250K StyI or Il-
lumina 610-Quad—at the W.M. Keck Foundation Biotech-
nology Resource Laboratory at Yale University. Genotyp-
ing data were analyzed with in-house-developed software
for the identification of regions of homozygosity (ROHs)
throughout the genome, and genes known to be mutated
in WWS were sequenced whenever they were contained
in a ROH present only in the affected individual. As we
previously reported,6 homozygous mutations were found
in eight families (8 of 19; 42%) (Table S1). Homozygosity
analysis of the remaining 11 families identified an average
percentage of homozygosity of 9.3% (1.3% 5 standard
error of the mean), which is larger than the expected 6%
for a first-cousin union10 and suggests increased back-
ground consanguinity that could not be captured by the
available nuclear pedigrees (Table S1). Multiple regions
were shared between at least two families, as expected by
chance in this type of cohort, but the fact that no region
overlapped in more than three families indicates that
multiple additional genes remain to be identified.
The percentage of homozygosity in the cohort was high
but was sufficient to reduce the number of candidate genes
to a few hundred or thousand per sample. Therefore, we
performed whole-exome sequencing (WES) analysis to
study all candidate genes at once.11 Seven of the remain-
ing probands were suitable for WES, and whole-exome
DNA libraries were prepared from genomic DNA by
hybridization with the Agilent SureSelect All Exon 37Mb
kit and were run on an Illumina HiSeq2000 machine
either at the Duke Center for Human Genome Variation
in Durham, NC or at the Broad Institute of MIT and
Harvard in Cambridge, MA. Sequencing reads were
aligned to the Human Reference Genome (UCSC hg19)
with Burrows-Wheeler Aligner software.12 Variant calling
was performed with SAMtools software,12 and either
SequenceVariantAnalyzer or ANNOVAR13 was used for
annotating variants. Sequencing yielded an average of
49,538 variants per individual (see Table S2 for WES statis-
tics). Variants were then filtered with custom MySQL
queries for the identification of recessive mutations, which542 The American Journal of Human Genetics 91, 541–547, Septembwere (1) most likely pathogenic (missense or nonsense
variants, frameshift indels, or splicing errors within
10 bp of the splice site), (2) novel or rare (minor allele
frequency < 0.5%) in a control cohort of more than
7,000 control individuals (1,000 Genomes November
2011 release, 5,379 exomes from the National Heart,
Lung, and Blood Institute [NHLBI] Grand Opportunity
Exome Sequencing Project, 69 genomes from Complete
Genomics, and 821 in-house Walsh lab exomes), (3) found
in a ROH in the propositus, and (4) found to be inherited
in an autosomal-recessive pattern in the family upon
Sanger sequencing of the parents and unaffected siblings.
Filtered variants from Middle Eastern individuals, who are
not widely represented in the exome databases, were
also genotyped in at least 384 ethnically matched individ-
uals with mass-spectrometry-based Sequenom SNP geno-
typing at the Intellectual and Developmental Disabilities
Research Center (IDDRC) Molecular Genetics Core at
Boston Children’s Hospital for confirming that the vari-
ants were not rare population-specific polymorphisms.
This approach narrowed the number of variants to an
average number of five candidates per family (Table S2).
Homozygous mutations in genes known to be involved
in WWS were identified in affected individuals in two
families (Figure S1); these were a homozygous 1 bp inser-
tion leading to a frameshift change (c.642dup [p.Asp215*])
(NM_006731.2) in FKTN in family 82, a first-cousin
union of Hispanic ethnicity from the United States (Table
1 and Figures S1A and S1B), and a homozygous missense
change (c.1433A>G [p.His478Arg]) (NM_013382.4) in
POMT2 in family 144, a second-cousin union from
Sudan (Table 1 and Figures S1C and S1D). The missense
change obtained the highest pathogenicity score in two
independent pathogenicity prediction algorithms, Poly-
phen214 and SIFT15 (Polyphen2 ¼ 1 [probably damaging];
SIFT ¼ 0 [damaging]). Despite being present in a large
ROH in the affected individuals, these genes had not
been previously sequenced because in each family, a
smaller homozygous region with an identical haplotype
was present over the gene of interest in one of the parents
and was most likely due to a common haplotype in theer 7, 2012
Figure 1. Three Independent Alleles in GTDC2 Cause WWS
(A) Pedigree structure of family 90 (DNA was available for individuals marked by asterisks) and T2-weighted axial magnetic resonance
images (MRIs) of the propositus. The MRI on the left shows microphthalmia and macrophthalmia (asterisks) and cerebellar hypoplasia
(red arrow), and the MRI on the right shows severe ventricular enlargement and cortical-migration defects characteristic of cobblestone
lissencephaly (inset).
(B) Pedigree structure of family 100 and coronal MRIs of the propositus. These images show a degree of malformation similar to that
seen in family 90.
(C–D) Sanger sequencing confirming the mutations identified by WES in families 90 and 100.
(E) Conservation of arginine 158 and the surrounding region in vertebrates.
(F) Sanger sequencing of an additional GTDC2 nonsense mutation identified in family 86.
(G) Schematics showing overlapping regions of homozygosity in the three families affected by GTDC2 mutations and the GTDC2
protein structure including predicted functional domains. Locations of the mutations are listed above the protein.population. These findings illustrate the power of WES to
identify disease-causing mutations in an unbiased
manner because all known disease genes can be tested
independently.
We then analyzed the variants in the remaining WWS-
affected families and identified two independent homozy-
gouschanges inglycosyltransferase-likedomain-containing
2 (GTDC2), a single-exon gene on the short arm (3p22.1) of
chromosome 3 (Figure 1). The first variant was a nonsense
change (c.1333C>T [p.Arg445*]) (NM_032806.4) in a male
from a Jordanian first-cousin union (family 90, Figure 1C)
and led to a possible early truncation of GTDC2 (Figure 1G);
the second variant was a missense change predicted to
be very deleterious and affected a conserved amino acid
(c.473G>A [p.Arg158His]; Polyphen2 ¼ 1 [probably
damaging] andSIFT¼0 [damaging]) ina female fromaSaudi
family (family 100, Figures 1D and 1E). Each change was
contained in a large ROH: 25.8 Mb and 28.1 Mb in familiesThe American90 and 100, respectively (Figure 1G). The phenotypes of
the two families were undistinguishable from each other
and from that of classic WWS cases—they included
cobblestone lissencephaly, severe hydrocephalus, severe
hypoplasia of the cerebellar vermis, and muscle hypotonia
(Table 1 and Figures 1A and 1B). No muscle biopsy was
performed because all affected individuals died within
a few days or weeks of birth.
WWS is the most severe of a spectrum of dystroglycan-
glycosylation disorders affecting the muscle, eyes, and
brain. It has variable severity and is commonly defined as
muscular-dystrophy dystroglycanopathies (MDDGB1–6
[MIM 613155, 613156, 613151, 613152, 606612, and
608840] and MDDGC1–5 and MDDGC7 [MIM 609308,
613158, 613157, 611588, 607155, and 613818]).7,9,16 We
sequencedGTDC2 in a validation cohort of nonconsangui-
neous cases (n ¼ 52) spanning the dystroglycanopathy
phenotypic spectrum to identify additional alleles. WeJournal of Human Genetics 91, 541–547, September 7, 2012 543
Figure 2. Expression of GTDC2 and Its
Orthologs in Mice and Zebrafish
(A) qPCR analysis ofGTDC2mRNA expres-
sion in fetal and adult human tissues. High
expression was found at both stages in the
brain, muscle, kidneys, and heart. In the
adult brain, the cerebellum and cortex
had the highest expression. Error bars
represent the standard error across three
sample repeats normalized to beta-actin.
(B) Murine Gtdc2 is expressed during brain
development. At E14.5 (left panels),
expression is observed throughout the
cortical plate (cp) and the developing
brain, as well as throughout the eye,
including the lens and cornea. No staining
was evident in the sense control. The scale
bars in the left panels represent 200 mm.
Cortical expression (right panels) peaks
between E14.5 and E16.5 and is reduced
at birth (P0). The scale bar in the right
panel represents 100 mm.
(C) In situ hybridization of zebrafish gtdc2
at 1 dpf shows expression throughout the
body; the highest staining is in the brain
and eye and at the boundaries between
somites (arrowheads and inset). The scale
bar represents 150 mm.identified an additional nonsense allele in family 86, an
Indian family in which two pregnancies were terminated
as a result of a diagnosis of ventricular enlargement during
gestation. Both fetuses were female and were diagnosed
with WWS upon autopsy (Table 1). DNA was available
from one of the two affected individuals, and sequencing
revealed a homozygous GTDC2 mutation (c.590G>A)
generating a stop codon at amino acid 197 (p.Trp197*;
Figure 1F). The family displayed a small total amount of
homozygosity (1%)—only two regions were larger than
5 cM, and GTDC2 was contained in the largest (7.5 Mb and
5.9 cM) of these regions on chromosome 3 (Figure 1G)—
suggesting that the parents might be distantly related.
GTDC2 is an ideal candidate gene for WWS because
it is predicted by multiple protein-domain prediction algo-
rithms to contain an uncharacterized glycosyltransferase
domain (Figure 1G). All genes in which mutations have
been identified to date are involved in glycosylation of
the transmembrane protein dystroglycan, which must be
glycosylated in order to interact with extracellular matrix
components such as laminins, and this binding is essential
for brain, eye, andmuscle integrity.2,17–19GTDC2 (which is
alternatively called AGO61) is predicted by homology to
belong to glycosyltransferase family 61, and, similar to544 The American Journal of Human Genetics 91, 541–547, September 7, 2012LARGE (another gene involved in
dystroglycanopathies), it is also pre-
dicted to encode a xylosyltrans-
ferase.20 We studied expression of
GTDC2 mRNA in multiple human
tissues by using quantitative PCR
(qPCR) both during fetal develop-ment and in the adult. cDNA samples from postmortem
fetal and adult human tissues were obtained commercially
(BioChain Institute and Clontech). qPCR was performed
with SYBR Green reagents (Applied Biosystems) on an
ABI 7500 qPCR platform as previously described21 with
primers hGTDC2_F 50-GCGGAGTCCAGGCTTCAGGCT
TTC-30 and hGTDC2_R 50-CCGCCGAGAGGTGCATCCT
AATG-30 and normalizing expression values to beta-actin
(ACTB).
At both fetal and adult stages, GTDC2 expression was
especially high in the brain, muscle, heart, and kidneys
(Figure 2A), which are all variably affected in dystroglycan-
opathy cases.6,22 Brain expressionwas highest in the cortex
and cerebellum (Figure 2A), and very high expression was
also noted in the pancreas (Figure S2A). To analyze possible
changes in cellular distribution, we analyzed expression of
themurine ortholog ofGTDC2,Gtdc2, by in situ hybridiza-
tion (performed at the In Situ HybridizationCore Facility at
the University of North Carolina School of Medicine in
ChapelHill, NC)with a probe amplified froman embryonic
day (E)12.5 mouse brain cDNA library (a kind gift of
Byoung-Il Bae at Boston Children’s Hospital) (primers
were mGtdc2-forward 50-TTCCCTTACGCTGTCAATCC-30
and mGtdc2-reverse 50-TACGTGTTCTCCCCTTGCTC-30).
We found that Gtdc2 is highly expressed during brain and
eye development; it peaks in the cerebral cortex during
the last week of gestation in both neuronal progenitors in
the ventricular zone and migrating and differentiating
neurons but declines around birth, supporting a role for
this gene during neuronal development (Figure 2B), but
we did not observe differential expression in neuronal
progenitors or neuronal subtypes.
To test how GTDC2 loss of function would affect brain
and muscle development, we used the zebrafish, which
has been recently established as an animal model for
dystroglycanopathies.23–26 The mRNA for the zebrafish
ortholog (gtdc2) of GTDC2 was expressed in the zebrafish
embryo and larva throughout development; there was
especially high expression in the developing brain, eyes,
and somites (Figure 2C and Figure S2B), consistent with
expression of the zebrafish orthologs of other genes
mutated in WWS.27,28 Zebrafish in situ hybridization was
performed according to standard protocols29 with a probe
amplified with a mixed 20-somite to 5 day postfertilization
(dpf) zebrafish cDNA library (a kind gift of Peter Wang at
Boston Children’s Hospital) (primers were zfgtdc2-forward
50-ATGCACATTTTCCACGATGA-30 and zfgtdc2-reverse
50-AACGACTGCTCCTCCAAAGA-30). To knock down
gtdc2, we tested two different antisense morpholino oligo-
nucleotides (MOs) targeted to interfere with gtdc2 trans-
lation by either blocking the start codon (gtdc2Start:
50-CCGGCAGGTTCATCCTACACCCGAT-30) or the splice
donor site in the only intron present in this gene in
the fish (gtdc2Splice: 50-TTATCATAACCCTGTGCACCT
GTGA-30). When these MOs were injected into fertilized
zebrafish oocytes, they provided similar results (gtdc2Start
at 3–5 ng and gtdc2Splice at 7–10 ng). Therefore, data from
only gtdc2Start will be shown. The standard control MO
provided by Gene Tools was used as a control at the same
concentration used for the experimental MO injections.
Injected embryos/larvae and uninjected clutchmate
controls were analyzed at 0, 1, 2, and 3 dpf for survival
and morphology of the tail, head, and eyes. Develop-
mental defects in gtdc2 morphants were evident from 1
dpf—one quarter of the embryos were severely affected
with a very short body, thick and poorly developed tail,
and no discernible eyes or head structures. Half of the
morphants were mildly affected and were scored on a
combination of phenotypes: thick tail, U-shaped somites,
reduced mobility inside the chorion, a small head, and
underdeveloped eyes, where ventral fusion of the retina
was delayed (Figure 3A). We asked whether coinjection of
the in-vitro-synthesized human GTDC2 mRNA with the
gtdc2 MO could improve these phenotypes and found
this to be the case (Figure 3B). However, almost no rescue
effect was observed when we tested the mRNA mutated
to include the p.Arg158His allele (Figure 3C). The Arg158
residue is highly conserved in GTDC2, and it is located at
the beginning of the glycosyltransferase domain; there-
fore, it is possible that this change might severely impair
protein function.The Americangtdc2 knockdown severely affected survival: 43.4% of
embryos died within the first 3 days after injection.
However, clutchmates that were uninjected or injected
with a control MO displayed survival rates of 98.4% and
89.0%, respectively (Figure S3A). Surviving morphants at
3 dpf were shorter than controls and often had a bent
tail, impaired motility, smaller eyes in which the retina
failed to fuse ventrally, and a domed appearance of the
top of the head (Figures 3D and 3G and Figure S3B).
When pigmentation was blocked at 1 dpf with the
addition of 0.003% 1-phenyl 2-thiourea to the water,
external analysis of the head revealed extreme ventricular
enlargement (hydrocephalus), often accompanied by
hemorrhaging (Figure 3G), in the most affected larvae (Fig-
ure 3E). Ventral compression and reduction in brain
volume were evident upon histological analysis of coronal
cryosections stained with DAPI (Figure 3E). Disorganiza-
tion of the retinal epithelium was also observed in a few
morphants; there was variable severity in ultrathin
plastic-embedded sections stained with 1% toluidine blue
and 1% sodium borate (Figure S3C) at the Conventional
Electron Microscopy Facility at Harvard Medical School.
Finally, muscle development was severely disrupted by
a loss of both dystrophin and glycosylated dystroglycan
from the myosepta, the junction of muscle fibers in
which the extracellular matrix is enriched (Figure 3F).
Disorganization of the muscle fibers was also observed
upon histology (Figure S3D). These phenotypes (hydro-
cephalus and retinal and muscle defects) are the hallmarks
of WWS and are consistent with the eye, muscle, and
brain phenotypes observed in morphants of genes (such
as POMT1, POMT2, FKTN, FKRP, and ISPD) previously
found to be mutated in WWS.24–26,28 All phenotypes
were ameliorated by GTDC2 mRNA injections when
embryos were analyzed at 2 and 3 dpf (Figure 3G and
Figure S3E).
In summary, we have combined whole-exome se-
quencing, homozygosity mapping, and functional anal-
ysis in zebrafish to identify and validate GTDC2mutations
as a cause of WWS. In addition, we have reduced the
number of candidate variants in other families to a
manageable number of five variants per family. This
approach will most likely yield additional mutated genes
in the future to help unravel the pathways involved in
WWS and to determine the role of different glycosyltrans-
ferases in brain and muscle development.Supplemental Data
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Figure 3. Loss of gtdc2 in the Zebrafish
Embryo Recapitulates Phenotypes Ob-
served in WWS
(A) Mild (center) and severe (right) pheno-
types observed in the 1 dpf zebrafish
embryo after injection of a MO designed
against the start site of gtdc2.
(B) Phenotypes observed at 1 dpf can be
rescued by coinjection of the gtdc2 MO
and 150 pg of GTDC2 mRNA, whereas no
effect is observed by injection of the
mRNA alone (hGTDC2).
(C) Coinjection of 150 pg of GTDC2
mRNA containing the p.Arg158His alter-
ation is not able to rescue the morphant
phenotype. Representative experiments
are shown.
(D) Surviving morphants at 3 dpf show
several developmental defects: reduced
length, bent tail, failure of ventral retinal
fusion, and dysmorphic head shape.
(E) 3 dpf morphants also display hydro-
cephalus (lower left panel: whole-mount
of nonpigmented larva [asterisk]) and
ventral compression of the remaining
brain tissue (lower right panel: DAPI stain-
ing on histological section at a location
matching the wild-type [WT] section
above). The scale bar represents 200 mm.
(F) Immunohistochemistry in sections
of the WT and morphant muscle shows
that expression of both dystrophin
(green, left) and glycosylated dystroglycan
(green, right) are reduced at the myosepta
(marked by arrowheads). Nuclei are
labeled in DAPI (blue). The scale bar repre-
sents 50 mm.
(G) Rescue with GTDC2 mRNA (on
right) ameliorates the most severe head
phenotypes observed in the morphant
(center). These phenotypes are failure of
retinal fusion (arrowhead), hydrocephalus
(asterisk), and hemorrhage (arrow). The
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